Substance P‐induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man

Open Access
Publisher Website
Google Scholar
Abstract
Aims Following intravenous administration of its prodrug, L‐758,298, we assessed the pharmacodynamics of L‐754,030, a novel and highly selective NK1 receptor antagonist, by examining systemic haemodynamics and the blood flow responses to intra‐arterial substance P infusion. Methods Sixteen healthy male volunteers participated in a double‐blind, randomised, placebo controlled crossover trial of L‐758 298. Forearm blood flow was measured using venous occlusion plethysmography during intrabrachial substance P infusion (0.125–128 pmol min−1 ). In part 1, eight subjects received substance P infusions before and during placebo, 0.25 mg, 1 mg or 5 mg of L‐758 298. In part 2, eight subjects received substance P infusions 24 h after placebo or 1.43 mg of L‐758 298. Results L‐758 298 caused dose dependent inhibition of substance P induced vasodilatation (P1400–fold shift in substance P response): 0.00 (−0.49 to +0.49) ml 100 ml−1 min−1, 1.0 (−3.2 to +5.2) mmHg and 1.9 (−5.9 to +9.7) beats min−1, respectively. Twenty‐four hours after 1.43 mg of L‐758,298, there was ~34–fold shift in response to substance P induced vasodilatation (P−1. L‐758 298 was generally well tolerated without serious adverse events. Conclusions Substance P induced forearm vasodilatation is mediated by the endothelial cell NK1 receptor in man but endogenous substance P does not appear to contribute to the maintenance of peripheral vascular tone or systemic blood pressure.